Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2021-04-19 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2020年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as an announcement of the resolutions from the 2020 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the meeting date, attendance, voting results on various proposals including the 2020 annual report, profit distribution plan, and election of an independent director. The document is a formal announcement of the voting results and decisions made at the AGM, rather than the full annual report or other detailed financial disclosures. The length is under 5,000 characters and it primarily reports the outcomes of shareholder votes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-04-19 Chinese
2020年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2020 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It discusses the legality and validity of the AGM's convening, attendance, voting procedures, and results. The document references the AGM date, voting results, and compliance with relevant laws and company articles. It does not contain the actual annual report or financial statements but rather focuses on the AGM process and voting outcomes. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document length is about 5741 characters, which is sufficient for a detailed voting results announcement rather than a brief report publication announcement. Therefore, the correct classification is DVA.
2021-04-19 Chinese
关于对外投资的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceutical Co., Ltd. regarding the progress of an external investment involving the establishment of subsidiaries in the British Virgin Islands and Cayman Islands, as well as capital injections and equity acquisitions. It details the registration completion of these subsidiaries and provides company registration information. The document is short (1224 characters) and focuses on corporate investment and structural updates rather than financial results or detailed reports. It does not contain financial statements or detailed financial analysis. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2021-04-15 Chinese
关于举行2020年年度报告网上说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding an online explanation meeting for the 2020 annual report. It references that the 2020 annual report and its summary have already been disclosed on March 30, 2021. The document invites investors to participate in a webcast to discuss the annual report, including details on how to join and who will attend. The document itself does not contain the annual report or detailed financial data but is a notice about an investor presentation event related to the annual report. Therefore, it fits the category of an Investor Presentation (IP) announcement rather than the annual report itself or a report publication announcement.
2021-04-12 Chinese
关于SAL0104胶囊获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of a clinical trial for a drug (SAL0104 capsule) by the National Medical Products Administration. It contains no financial data, no mention of financial results, no detailed report or presentation, and is primarily an official notification about regulatory approval for clinical trials. The document length is only 588 characters, indicating it is a brief announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any financial filings. It is a regulatory announcement about drug trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2021-03-30 Chinese
关于深圳信立泰药业股份有限公司2020年度业绩下滑事项的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed special investigation opinion by a securities firm regarding the 2020 annual performance decline of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes audited financial data for 2020, analysis of reasons for performance decline, risk disclosures, impact on ongoing capital raising (non-public issuance of A shares), and compliance with regulatory requirements. The document references the 2020 annual report and audit opinions but is itself a regulatory compliance and due diligence report related to a capital raising event. It does not constitute the annual report itself but is a specialized audit and investigation report on performance decline and its impact on financing. The document length (9109 characters) and content indicate it is not a brief announcement or a simple certification but a substantive audit-related report. Therefore, the best fitting category is Audit Report / Information (AR). FY 2020
2021-03-30 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.